Four Mechanisms of Peptide-Mediated Fat Loss
Fat loss peptides do not all work the same way. Understanding the underlying mechanism is essential for interpreting the research literature and selecting the appropriate compound for a given research question.
GLP-1 and GIP receptor agonists (semaglutide, tirzepatide, retatrutide) act on hypothalamic satiety centers and slow gastric emptying, reducing caloric intake. This is the mechanism with the strongest human clinical evidence.
GHRH analogues (tesamorelin, CJC-1295) stimulate pituitary GH release, which activates hormone-sensitive lipase in adipocytes. Particularly effective for visceral adipose tissue reduction.
GH fragments (AOD-9604, HGH Fragment 176-191) retain the C-terminal lipolytic domain of GH without its growth-promoting effects, directly stimulating fat breakdown in adipose tissue.
Mitochondrial peptides like MOTS-c activate AMPK, enhancing fatty acid oxidation and insulin sensitivity — mimicking the metabolic adaptations of exercise at the cellular level.
Ranked Compound Profiles
Tesamorelin
High EvidenceStimulates pituitary GH release → elevates IGF-1 → promotes lipolysis, particularly visceral adipose tissue (VAT) reduction
FDA-approved (as Egrifta) for HIV-associated lipodystrophy; multiple Phase III trials demonstrate significant VAT reduction vs placebo
Retatrutide
High EvidenceSimultaneous agonism of GIP, GLP-1, and glucagon receptors → appetite suppression, increased energy expenditure, enhanced lipolysis
Phase II trial (NEJM 2023) showed mean body weight reduction of 17.5% at 24 weeks — among the highest reported for any peptide compound
Semaglutide
High EvidenceActivates GLP-1 receptors in hypothalamus and gut → reduces appetite, slows gastric emptying, improves insulin sensitivity
STEP 1 trial: 14.9% mean body weight reduction vs 2.4% placebo at 68 weeks; FDA-approved for chronic weight management (Wegovy)
Tirzepatide
High EvidenceCo-agonism of GIP and GLP-1 receptors → superior appetite suppression and metabolic improvement vs GLP-1 alone
SURMOUNT-1 trial: up to 22.5% mean body weight reduction at 72 weeks — surpassing semaglutide in head-to-head comparisons
AOD-9604
Moderate EvidenceC-terminal fragment of human GH that retains lipolytic activity without the growth-promoting or insulin-desensitizing effects of full GH
Preclinical studies show selective stimulation of lipolysis and inhibition of lipogenesis; human trials limited but safety profile well-characterized
CJC-1295 + Ipamorelin
Moderate EvidenceDual-pathway GH stimulation → sustained IGF-1 elevation → enhanced lipolysis and lean mass preservation
Indirect fat loss via GH-mediated lipolysis; studied primarily for body composition changes alongside lean mass research
HGH Fragment 176-191
Emerging EvidenceSame mechanism as AOD-9604 — isolated lipolytic domain of GH without anabolic or diabetogenic effects
Rodent studies demonstrate 12x greater fat-burning activity than full GH; human data limited to early-phase safety studies
MOTS-c
Emerging EvidenceActivates AMPK → improves insulin sensitivity, enhances fatty acid oxidation, mimics exercise-induced metabolic adaptations
Preclinical studies show prevention of diet-induced obesity and improved metabolic flexibility; human trials ongoing
Quick Comparison
| Compound | Mechanism | Best For | Evidence | Muscle Sparing |
|---|---|---|---|---|
| Tesamorelin | GHRH → GH → Lipolysis | Visceral fat | High | Yes |
| Retatrutide | GIP+GLP-1+Glucagon | Total body weight | High | Partial |
| Semaglutide | GLP-1 agonist | Appetite / weight | High | Partial |
| Tirzepatide | GIP+GLP-1 dual | Appetite / weight | High | Partial |
| AOD-9604 | Direct lipolysis | Selective fat burning | Moderate | Yes |
| CJC-1295 + Ipa | GHRH+GHRP → GH | Body composition | Moderate | Yes |
| HGH Frag 176-191 | Direct lipolysis | Selective fat burning | Emerging | Yes |
| MOTS-c | AMPK activation | Metabolic flexibility | Emerging | Yes |
"High evidence" compounds in this guide (tesamorelin, semaglutide, tirzepatide, retatrutide) have substantial human clinical trial data. "Moderate" and "Emerging" compounds have primarily preclinical (animal) data or limited early-phase human studies. Evidence level reflects the depth of the research literature, not a safety or efficacy endorsement. All compounds on this page are research chemicals not approved for human use outside of specific FDA-approved indications.
Frequently Asked Questions
What are peptides for fat loss and how do they work?
Fat loss peptides are synthetic or naturally-derived amino acid chains that influence metabolic pathways involved in adipose tissue regulation. They work through several distinct mechanisms: GLP-1 and GIP receptor agonists (like semaglutide and tirzepatide) primarily reduce appetite and caloric intake; GHRH analogues (like tesamorelin) stimulate GH-mediated lipolysis; GH fragments (like AOD-9604) directly activate lipolytic enzymes in adipose tissue; and mitochondrial peptides (like MOTS-c) enhance fatty acid oxidation at the cellular level.
Which peptide has the strongest evidence for fat loss?
By clinical trial evidence, tesamorelin, semaglutide, and tirzepatide have the strongest human data. Tesamorelin is FDA-approved for visceral fat reduction. Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management with Phase III trials showing 15–22% body weight reductions. Retatrutide showed the highest weight loss percentage in Phase II data (17.5% at 24 weeks) but is still in clinical development.
Is AOD-9604 the same as HGH Fragment 176-191?
Yes — AOD-9604 and HGH Fragment 176-191 refer to the same compound: the C-terminal fragment of human growth hormone spanning amino acids 176–191. The name AOD-9604 was used in clinical development by Metabolic Pharmaceuticals. Both names appear in the research literature and refer to the identical peptide sequence.
Do fat loss peptides preserve muscle mass?
This varies significantly by mechanism. GH-stimulating peptides (tesamorelin, CJC-1295/Ipamorelin) tend to preserve or increase lean mass alongside fat loss, as GH promotes both lipolysis and protein synthesis. GLP-1 agonists (semaglutide, tirzepatide) produce fat loss primarily through caloric restriction, and some studies have noted lean mass loss alongside fat loss — though this is common with any significant caloric deficit. MOTS-c's exercise-mimicry mechanism may support lean mass preservation through AMPK activation.
What is the difference between visceral fat and subcutaneous fat in peptide research?
Visceral adipose tissue (VAT) surrounds internal organs in the abdominal cavity and is metabolically more active and associated with greater cardiometabolic risk than subcutaneous fat (which lies beneath the skin). Tesamorelin is specifically noted in the literature for its preferential reduction of VAT. GLP-1 agonists reduce both types. GH fragments like AOD-9604 appear to target lipolysis broadly. Researchers often use DEXA scans or CT imaging to distinguish between these compartments in clinical studies.
How does retatrutide compare to semaglutide for fat loss?
Retatrutide is a triple agonist (GIP + GLP-1 + glucagon receptors) while semaglutide is a single GLP-1 agonist. In Phase II data, retatrutide showed a mean 17.5% body weight reduction at 24 weeks at the highest dose, compared to approximately 10–15% for semaglutide at comparable timepoints. The additional glucagon receptor agonism in retatrutide is believed to contribute to increased energy expenditure beyond the appetite suppression seen with GLP-1 alone. Retatrutide is still in Phase III trials as of early 2026.
Related Guides & Compound Profiles
Key Published Research
Peer-reviewed studies from verified investigators — linked directly to PubMed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults (STEP 3)
Wadden TA, Bailey TS, Billings LK, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee C, Zeng J, Drew BG, et al.
All citations link to verified PubMed records. This site does not fabricate or assign authorship — only real published investigators are listed.
Research These Compounds at Purgo Labs
Third-party tested, ≥99% purity, COA with every batch.